A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease
Summary
Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated with excessive glutamate release and calcium overload in neurons. Previous studies have shown that memantine helps to treat the symptoms of Alzheimer's Disease (AD). In AD, the rate of brain tissue loss, or atrophy, is faster than in normal aging and this seems to go hand in hand with some of the symptoms of the disease. This suggests that memantine treatment in AD could provide both symptomatic improvement and neuro-protective effects. The purpose of this study was to show whether memantine, in addition to providing symptomatic benefits, can slow the rate of brain atrophy as assessed using magnetic resonance imaging (MRI) technology.
Timeline
- Start
- 2005-09
- Primary completion
- 2009-02
- Completion
- 2009-04
Outcome
Missed primary endpoint
registry p = 0.9754; Adjusted mean difference -0.04 (95% CI -2.60 to 2.52) NCT00862940 ↗
paper the differences in TBA rates between memantine (15.2 mL/year) and placebo (15.3 mL/year) were not statistically significant PMID 22269160 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Memantine | Unknown | 10 mg | Oral |